According to filings with the U.S. Securities and Exchange Commission, Antiva Biosciences is raising $52,999,990.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kristine Ball played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Antiva Biosciences

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3). The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antivas chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.

To learn more about Antiva Biosciences, visit http://www.antivabio.com/

Contact: Kristine Ball, Chief Executive Office 650-822-1400

SOURCE: http://www.intelligence360.io Copyright (c) 2023 SI360 Inc. All rights reserved.